2020-12-13 网络 网络



Britain has become the first country in the West to approve a COVID-19 vaccine for public use. The UK Department of Health and Social Care confirmed in a statement to British news agencies that the vaccine developed jointly by American drugmaker Pfizer and Germany's BioNTech would be distributed starting next week. Pfizer was the first of three major Western pharmaceutical companies to apply in both the US and Europe for emergency use authorization.


"The Government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer/BioNTech's Covid-19 vaccine for use," a Department of Health and Social Care spokesman told the Press Association of Britain. The spokesman said the emergency use authorization followed "months of rigorous clinical trials and a thorough analysis of the data by experts at the MHRA who have concluded that the vaccine has met its strict standards of safety, quality and effectiveness."


In line with planning in the US, British front-line healthcare workers, care home residents, the very elderly and people with underlying conditions that make them particularly vulnerable to COVID-19 complications are expected to get the first doses of the vaccine. Pfizer's vaccine, like the Oxford and Moderna formulas, requires two doses about a month apart.


UK Health Secretary Matt Hancock called it "fantastic news" that Britain's regulator had deemed the first vaccine safe, and vowed that distribution would begin from Monday. He told the BBC Breakfast show that vaccinations would "start with the most elderly and with people in care homes."


Prime Minister Boris Johnson also hailed the news, confirming in a tweet plans to start rolling out doses from next week.



Screenshot from CBS website

"It's the protection of vaccines that will ultimately allow us to reclaim our lives and get the economy moving again," Johnson said.


Hancock, Britain's top public health official, noted the logistical complexities of distributing the Pfizer vaccine, which needs to be stored at around -94 degrees Fahrenheit, but said Britain would get its first 800,000 doses delivered next week. The UK has a total of 40 million doses of the Pfizer vaccine on order, enough to fully treat 20 million people.


Two other vaccines, one developed by US-based Moderna, which also requires sub-zero storage, and one made by British pharmaceutical company AstraZeneca in conjunction with Oxford University, have also applied for emergency use authorization in the US and Europe.


Both Pfizer and Moderna have said that data from large-scale human trials, involving tens of thousands of people, showed their vaccines to be about 95% effective at preventing COVID-19 infection. AstraZeneca/Oxford found their vaccine, which works in a different way, was up to 90% effective with a certain dosing regimen. The Oxford-developed vaccine is much cheaper to produce, and to distribute as it only requires storage at refrigerator temperatures.


Pfizer chief executive Albert Bourla called the UK move "a historic moment in the fight against COVID-19."


None of the human trials on any of the three leading Western-made vaccines have found significant adverse affects. Some side effects commonly associated with long-used vaccines, including soreness around the point of injection, fatigue and headaches have been seen in the trial data.


Logistical issues aside, epidemiologists and public health officials worldwide have warned that another major hurdle to putting the coronavirus pandemic behind humanity could be mistrust of the vaccines that become available.


A CBS News poll carried out in early September found rising skepticism about the coronavirus vaccines in development, with most voters saying that if a vaccine were made available this year, their first thought would be that it was rushed through without enough testing.


Just 21% of voters nationwide said in the survey that they would get a vaccine as soon as possible if it were available at no cost, which was down from 32% in a survey conducted in late July. Most said they would consider it, but wait to see what happens to others before getting one themselves.


This pandemic has seen pharmaceutical companies and research institutes work with governments and independent regulatory agencies to compress the usually-years-long process of developing and approving vaccines into a much shorter time frame.


The pace has been completely unprecedented, but the entities involved, along with outside experts in infectious disease and vaccinology, have insisted throughout that the process is being compressed safely, largely by overlapping steps that normally come sequentially, rather than by eliminating any steps in the trial and certification process.


Hancock, the British government's health chief, told UK broadcaster Piers Morgan on Wednesday that, if they could get it approved even though they weren't in a high-risk group, he would happily get vaccinated live on television next week with Morgan to show his trust in the vaccine.


评论区 (0)







双语已与减缓认知老化和老年痴呆后发性有关。在这项研究中,该研究的目的是确定是否双语也影响卒中后认知的结果。研究人员从一个大的卒中登记中研究了608例缺血性卒中患者,并研究了双语在无痴呆脑卒中患者中预测认知障碍的作用。与单语者相比,较大比例的双语者有正常认知(40.5% vs 19.6%,P<0.0001),而在认知功能障碍的患者中是相反的,包括血管性痴呆和血管性轻度认知障碍(单语者77.7%


P: Good morning, doctor.D: Good morning, please sit down. What seems to be the matter?P: I think I might have caught a cold.D: How long have you been sick?P: For two days.D: What symptoms do you have?


Coffee as a Health Drink? Studies Find Some Benefits 咖啡是否是一种健康饮料?   Coffee is not usually thought of as health food, but a number of recent studies suggest that it can be a highly beneficial drink.


Preeclampsia Study Favors Earlier Birth 早产对子痫前期孕妇有利   The number of fetuses and newborns to die because of a condition some women develop while pregnant has fallen as doctors perfect their timing in